



MARGARET W. BUSSE Executive Director MARK STEINAGEL Division Director

ANNOUNCEMENT

2025-2026 COVID-19 VACCINE GUIDANCE

The Division of Professional Licensing (DOPL) is issuing guidance clarifying the use of the 2025-2026 COVID-19 vaccine following the recommendations from the Advisory Committee on Immunization Practices (ACIP).

DOPL clarifies its current Vaccine Administration Guidance dated April 10, 2024 (and Vaccine Administration Protocol, revised September 2023), as follows:

 Utah pharmacists have the authority to prescribe and administer the 2025-2026 COVID-19 vaccine in accordance with the latest voted on and approved recommendations from ACIP. Pharmacists are also able to delegate the administration of 2025-2026 COVID-19 vaccine to trained pharmacy interns and pharmacy technicians.

While the recent ACIP recommendations shifted from a broad "should vaccinate" to a "shared clinical decision-making" model for most age groups, Utah's guidance and protocols with respect to those ACIP recommendations allow pharmacists to provide the vaccine to eligible patients without a prescription from another healthcare provider.

Pharmacists are also still authorized to administer any FDA-approved vaccine pursuant to a prescription or a collaborative practice agreement.

This document expires when the CDC approves and publishes the ACIP product-specific recommendations for the 2025-26 COVID-19 vaccine.

Mark B. Steinagel Division Director